Ladostigil

Drug Profile

Ladostigil

Alternative Names: Ladostigil hemitartrate; Ladostigil tartrate; TV-3326

Latest Information Update: 26 Aug 2015

Price : $50

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Avraham Pharmaceuticals
  • Class Antidementias; Carbamates; Indans; Neuroprotectants; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Monoamine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mild cognitive impairment
  • Discontinued Alzheimer's disease

Most Recent Events

  • 26 Aug 2015 Phase-II development for Mild cognitive impairment is ongoing in Austria, Germany and Israel
  • 28 Jul 2015 Interim efficacy data from a phase IIb trial in Mild cognitive impairment released by Avraham Pharmaceuticals
  • 08 Jul 2014 Interim efficacy & adverse events data from a phase IIb trial in Mild cognitive impairment released by Avraham Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top